- Design
- Systematic review and network meta-analysis of five randomised trials
- Population
- 4,227 adults with hypercholesterolaemia
- Primary outcome
- Percentage change in LDL cholesterol versus placebo
- Effect
- Up to −61.8 points (95% CI −78.1 to −45.5); MK-0616 20 mg −58.5 (−67.8 to −49.2)
A network meta-analysis in Endocrine (6 October) pooled five randomised trials (4,227 participants) of three oral PCSK9 inhibitors against placebo, treating each drug and dose separately.
All twelve drug–dose combinations lowered LDL cholesterol. The largest reductions, around 59% to 62% against placebo, came from the highest doses of two agents, including MK-0616 at 20 and 30 mg. No short-term safety signal emerged. Comparisons between agents were almost all indirect, and none of the differences among the top doses was significant.
Oral delivery would remove the injection, cold chain and some of the cost that keep injectable PCSK9 inhibitors under-used, which matters in India. But no outcome data are pooled here, certainty was rated low, and regulatory status varies; treat this as a preview.
- Expect LDL reductions near 60% at the highest doses, similar to injectable PCSK9 inhibitors
- Rankings between agents are uncertain; do not choose on these comparisons
- No cardiovascular outcome data are included in this analysis
- Check local approval before discussing these drugs with patients
Why it matters
An oral route could bring PCSK9 inhibition to patients who refuse or cannot store injections.
Don't overread it
LDL is a surrogate — the analysis does not show fewer heart attacks, and certainty was rated low.
The statistics, in plain English
The 95% CIs for the top doses are wide (about 47 to 78 percentage points), so the true reduction could be smaller or larger. An I² of 81% means trials disagreed, mostly because LDL was measured at different time points; at week 24 heterogeneity fell to zero.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for cardiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free